SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is surging following a report that the U.S. government plans to award the company $100 million in CHIPS Act funding in exchange for a minority equity stake. The community is buzzing over this validation of Infleqtion's neutral-atom technology and is actively debating how this sovereign backing differentiates it from other quantum peers in a rapidly evolving sector.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp is facing intense volatility as community members react to a polarizing earnings report, with heated debates over the company's growth, high operating expenses, and future potential in the fintech sector. While some investors are optimistic about upcoming platform updates and self-clearing capabilities, others are skeptical due to reported net losses and concerns over potential market manipulation during the release.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as investors digest the company's latest quantum research and commercial milestones alongside a broader sector rally fueled by new government funding initiatives. The community is actively debating the stock's valuation and long-term viability, with many traders focused on high-volatility price action and short-squeeze potential.

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.

Akari Therapeutics Plc - ADR

Akari Therapeutics

Akari Therapeutics is trending due to speculative investor excitement surrounding its lead antibody-drug conjugate candidate and potential synergies from its ongoing merger with Peak Bio. The community is actively discussing its low-float status and the possibility of a short squeeze as traders monitor the stock for significant volume spikes and management's efforts to regain NASDAQ compliance.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. is trending as part of a sector-wide rally driven by news that the U.S. government is providing $2 billion in funding to nine quantum computing companies in exchange for equity stakes. The community is actively debating the stock's fundamental valuation versus its speculative potential, with significant discussion focused on whether the government investment serves as a long-term validation of the sector or if the stock is susceptible to volatility from institutional profit-taking.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is drawing intense retail interest as investors seek a proxy for upcoming high-profile IPOs from SpaceX, OpenAI, and Anthropic. The stock is experiencing extreme volatility fueled by high short interest and social media sentiment, with many participants actively debating its valuation premium relative to Net Asset Value and the legal structure of its private asset holdings.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the market reacts to stronger-than-expected quarterly results and bullish delivery guidance, sparking intense debate between institutional bulls eyeing a turnaround and short sellers betting on continued volatility. Community discussion is dominated by accusations of market manipulation and calls for regulatory investigations, while long-term investors highlight the company's expanding gross margins and high vehicle demand as justification for a potential price re-rating.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently the subject of intense community debate following a 3-billion-dollar equity offering, which investors are weighing against its massive government contract wins and the upcoming SpaceX IPO. While some are concerned about the dilutive impact on share price, the broader sentiment remains heavily focused on the company's long-term potential as a critical player in the space defense sector.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is facing intense volatility as investors debate the sustainability of its premium valuation amidst broader semiconductor sector turbulence and reports of an antitrust probe into its licensing practices. While the community remains deeply divided, with many bears highlighting overvaluation concerns and insider selling, active traders are closely tracking the stock's price action against potential catalysts like the Cerebras IPO and ongoing momentum in AI-driven CPU demand.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is currently in the spotlight as investors weigh the company's defensive position against concerns over its elevated valuation and broader pressures from rising fuel and import costs. The community is actively debating the stock's stability as a retail bellwether while navigating conflicting sentiment regarding its high price-to-earnings ratio versus its long-term growth potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Houte Hans Van Sells 14,055 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 14,055 shares of the company's stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of...

Houte Hans Van Sells 2,388 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 2,388 shares of the company's stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an...

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fifteen analysts that are currently covering the firm, Marketbeat Ratings...

Nurix Therapeutics (NASDAQ:NRIX) CFO Houte Hans Van Sells 2,388 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 2,388 shares of the firm's stock in a transaction dated Thursday, April 30th. The shares were sold at an average price...

Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) Insider Sells 3,214 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) insider Gwenn Hansen sold 3,214 shares of Nurix Therapeutics stock in a transaction dated Thursday, April 30th. The stock was sold at an...

Pictet Asset Management Holding SA Acquires 1,487,060 Shares of Nurix Therapeutics, Inc. $NRIX

Pictet Asset Management Holding SA lifted its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 75.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,467,600 shares of the company's...

Nurix Therapeutics (NASDAQ:NRIX) Receives Buy Rating from HC Wainwright

HC Wainwright reissued a "buy" rating and set a $32.00 price target on shares of Nurix Therapeutics in a research report on Monday...

Needham & Company LLC Reiterates Buy Rating for Nurix Therapeutics (NASDAQ:NRIX)

Needham & Company LLC reiterated a "buy" rating and issued a $26.00 price objective on shares of Nurix Therapeutics in a research note on Thursday...

Sumitomo Mitsui Trust Group Inc. Sells 266,925 Shares of Nurix Therapeutics, Inc. $NRIX

Sumitomo Mitsui Trust Group Inc. trimmed its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 17.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1...

Q2 EPS Estimate for Nurix Therapeutics Lifted by Analyst

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - HC Wainwright raised their Q2 2026 earnings estimates for shares of Nurix Therapeutics in a report issued on Friday, April 10th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.73) per share for the quarter, up from t...

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.

Current Price	$17.53
Prev Close	$16.42
Open	$16.20
Dividend Yield	0.00%
50-Day Moving Average	$16.01
Beta	1.62
Avg. Volume	1.07M
PE Ratio	-5.55

52-Week High	$22.50
52-Week Low	$8.20
Market Capitalization	$1.7B
EPS (Annual)	-$3.05
Price to Book	3.77
Revenue Per Employee	$264,921.14

NRIX
Nurix Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest NRIX News

NRIXNurix Therapeutics Inc